
KNSA Stock Forecast & Price Target
KNSA Analyst Ratings
Bulls say
Kiniksa Pharmaceuticals is supported by a durable Arcalyst launch that continues to ramp despite only 23% penetration of the ~14,000 U.S. multiple-recurrence recurrent pericarditis market, leaving substantial room for expansion as prescriber breadth and earlier-line use increase. Its recent quarterly sales growth has averaged about $25MM, FY26 revenue guidance was raised to $1.045-$1.050B, and strong operating results show positive annual cash flow, with 3Q26 operating income of $54.2MM, net income of $47.3MM, and $568.8MM in cash and investments. The upside case is further strengthened by KPL-387, a wholly owned, once-monthly program with H2:2027 data expected that could improve adherence, support a gradual switch from Arcalyst, and lift EPS through better economics and additional pipeline optionality.
Bears say
Kiniksa Pharmaceuticals is vulnerable to slower-than-expected commercial adoption of Arcalyst in recurrent pericarditis, which undermines confidence in its ability to convert a clinical-stage portfolio into durable revenue growth. The outlook is further weakened by the risk that competing therapies could prove better than expected, limiting market share and reducing the long-term value of its programs. In addition, if biologics for rare diseases fail to secure premium pricing at commercialization, the company’s economics could disappoint, especially given its heavy reliance on the United States for revenue.
This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
KNSA Analyst Forecast & Price Prediction
Start investing in KNSA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kiniksa Pharmaceuticals Ltd (KNSA) Forecast
KNSA Analyst Forecast & Price Prediction
Start investing in KNSA
Order type
Buy in
Order amount
Est. shares
0 shares